Loading clinical trials...
Loading clinical trials...
ALS is a devastative disorder characterized by motor neuron degeneration. Median survival is 3 years after onset, but may vary from a few months to more than 30 years. Various factors have been suspec...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University Hospital, Montpellier
Collaborators
NCT07294144 · ALS (Amyotrophic Lateral Sclerosis)
NCT07233148 · Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), and more
NCT07369076 · Amyotrophic Lateral Sclerosis (ALS)
NCT03489278 · Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, and more
NCT07643896 · Pregnant Individuals, Aneuploidy, and more
University Hospital of Montpellier
Montpellier
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions